Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes

BMC Endocrine Disorders

Jan Frystyk¹  Tina Parkner⁵  Torsten Lauritzen²  Chunsen Wu³  Torben Laursen⁴  Jens Sandahl Christiansen¹  Zhulin Ma¹ 

[1] Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Nørrebrogade, DK-8000 Aarhus C, Denmark;Department of Public Health, Section of General Practice, Faculty of Health, Aarhus University, DK-8000 Aarhus C, Denmark;Department of Public Health, Section for Epidemiology, Faculty of Health, Aarhus University, DK-8000 Aarhus C, Denmark;Department of Biomedicine - Pharmacology, Faculty of Health, Aarhus University, DK-8000 Aarhus C, Denmark;Department of Clinical Biochemistry, Aarhus University Hospital, Nørrebrogade, DK-8000 Aarhus C, Denmark

关键词: IGFBP;    IGF;    Insulin analogue;    Insulin;   

Others  :  864932
DOI  :  10.1186/1472-6823-14-35

 received in 2013-11-19, accepted in 2014-04-01,  发布年份 2014

【 摘 要 】

Background

Insulin aspart (IAsp) and its biphasic preparations BIAsp50 and BIAsp70 (containing 50% and 70% IAsp, respectively) have distinct glucose-lowering properties as compared to human insulin (HI). We investigated whether this affected the circulating IGF-system which depends on the hepatic insulin exposure.

Methods

In a randomized, four-period crossover study, 19 patients with type 1 diabetes received identical doses (0.2 U/kg sc) of IAsp, BIAsp70, BIAsp50 and HI together with a standardized meal. Serum total IGF-I and IGFBP-1 to -3 were measured by immunoassays for nine hours post-prandially. Bioactive IGF was determined by an in-house, cell-based IGF-I receptor kinase activation (KIRA) assay.

Results

Despite marked differences in peripheral insulin concentrations and plasma glucose, the four insulin preparations resulted in parallel decreases in IGFBP-1 levels during the first 3 hours, and parallel increases during the last part of the study (3–9 hours). Thus, only minor significances were seen. Insulin aspart and human insulin resulted in a lower area under the curve (AUC) during the first 3 hours as compared to BIAsp70 (p = 0.009), and overall, human insulin resulted in a lower IGFBP-1 AUC than BIAsp70 (p = 0.025). Nevertheless, responses and AUCs of bioactive IGF were similar for all four insulin preparations. Changes in levels of bioactive IGF were inversely correlated to those of IGFBP-1, increasing during the first 3 hours, whereafter levels declined (-0.83 ≤ r ≤ -0.30; all p-values <0.05).

Total IGF-I and IGFBP-3 remained stable during the 9 hours, whereas IGFBP-2 changed opposite of IGFBP-1, increasing after 3–4 hours whereafter levels gradually declined. The four insulin preparations resulted in similar profiles and AUCs of total IGF-I, IGFBP-2 and IGFBP-3.

Conclusions

Despite distinct glucose-lowering properties, the tested insulin preparations had similar effects on IGF-I concentration and IGF bioactivity, IGFBP-2 and IGFBP-3 as compared to HI; only small differences in IGFBP-1 were seen and they did not affect bioactive IGF. Thus, insulin aspart containing preparation behaves as HI in regards to the circulating IGF-system. However, bioactive IGF appeared to be more sensitive to insulin exposure than total IGF-I. The physiological significance of this finding remains to be determined.

Trial registration

NCT00888732

【 授权许可】

   
2014 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007, 3:302-310.
• [2]Hedman CA, Frystyk J, Lindstrom T, Chen JW, Flyvbjerg A, Orskov H, Arnqvist HJ: Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab 2004, 89:6305-6309.
• [3]Ekman B, Nystrom F, Arnqvist HJ: Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur J Endocrinol 2000, 143:505-510.
• [4]Bereket A, Lang CH, Wilson TA: Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999, 31:172-181.
• [5]Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6:821-833.
• [6]Holt RI, Simpson HL, Sonksen PH: The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003, 20:3-15.
• [7]Frystyk J: The growth hormone hypothesis - 2005 revision. Horm Metab Res 2005, 37(Suppl 1):44-48.
• [8]Cingel-Ristic V, Flyvbjerg A, Drop SL: The physiological and pathophysiological roles of the GH/IGF-axis in the kidney: lessons from experimental rodent models. Growth Horm IGF Res 2004, 14:418-430.
• [9]The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The diabetes control and complications trial research group. N Engl J Med 1993, 329:977-986.
• [10]Reynolds NA, Wagstaff AJ: Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004, 64:1957-1974.
• [11]Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS: A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Diabetes Technol Ther 2012, 14:589-595.
• [12]Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Koerner A, Obermayer-Pietsch B, Hubener C, Dahlgren J, Frystyk J, Pfeiffer AF, Doering A, Bielohuby M, Wallaschofski H, Arafat AM: Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a New automated chemiluminescence IGF-1 immunoassay Conforming to recent international recommendations. J Clin Endocrinol Metab 2014, jc20133059. [Epub ahead of print]
• [13]Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J, Kratzsch J, Grabe HJ, Hubener C, Pfeiffer AF, Doering A, Bielohuby M, Dahlgren J, Frystyk J, Wallaschofski H, Bidlingmaier M: Age and sex specific reference intervals across life-span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I/IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab 2014, jc20133060. [Epub ahead of print]
• [14]Reinhard M, Frystyk J, Jespersen B, Bjerre M, Christiansen JS, Flyvbjerg A, Ivarsen P: Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol 2013, 14:80. BioMed Central Full Text
• [15]Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, Flyvbjerg A: Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003, 88:132-135.
• [16]Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De MP, Larsen MB, Christiansen JS, Frystyk J: A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003, 284:E1149-E1155.
• [17]Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994, 79:872-878.
• [18]Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801-831.
• [19]Frystyk J: Free insulin-like growth factors – measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004, 14:337-375.
• [20]Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson JM: Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44:333-339.
• [21]Katz LE, DeLeon DD, Zhao H, Jawad AF: Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab 2002, 87:2978-2983.
• [22]Frystyk J: Quantification of the GH/IGF-axis components: Lessons from human studies. Domest Anim Endocrinol 2011, 43:186-197.
• [23]Hedman CA, Orre-Pettersson AC, Lindstrom T, Arnqvist HJ: Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. Clin Endocrinol (Oxf) 2001, 55:107-112.
• [24]Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS, Frystyk J: Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 2006, 155:285-292.
• [25]Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 1989, 264:11843-11848.
• [26]Guler HP, Zapf J, Schmid C, Froesch ER: Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989, 121:753-758.
• [27]Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SC, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK, Crossey PA: IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007, 56:285-294.
• [28]Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, Mohlig M, Pfeiffer AF: The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 2009, 94:5093-5101.
• [29]Bereket A, Lang CH, Blethen SL, Wilson TA: Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. J Clin Endocrinol Metab 1995, 80:3647-3652.
• [30]Wheatcroft SB, Kearney MT: IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009, 20:153-162.
• [31]Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.